Prostaglandin-Free Lash Serums: What They Are and How to Choose

Part of Series on Lash Serum Safety

Last updated: May 9, 2026.

"Prostaglandin-free" defines a lash serum on its safety profile: a formulation that contains no ingredients from the prostaglandin analog chemical class. It is the safety counterpart to the quality framework defined on the medical grade vs cosmetic grade lash serums reference page. A serum can be cosmetic and prostaglandin-free, or medical grade and prostaglandin-free, or in rare cases prescription and prostaglandin-free. The two frameworks describe different dimensions of the same product. This page covers what "prostaglandin-free" actually means under regulatory and chemical definitions, why consumers seek prostaglandin-free options, the mechanisms used by serums that meet the criterion, and how to verify the claim against the full INCI ingredient list of any product.

Key Facts

• "Prostaglandin-free" describes a lash serum that contains no ingredients from the prostaglandin analog chemical class. Consumers can verify the claim by reading the full INCI ingredient list and checking for chemical names containing the fragments "-prost-" or "-cloprostenol-."
• The prostaglandin analogs most commonly found in cosmetic lash serums are isopropyl cloprostenate (IPCP), Ethyl Tafluprostamide (DDDE), and methylamido-dihydro-noralfaprostal (MDN). The European Union's Scientific Committee on Consumer Safety adopted Opinion SCCS/1680/25 on 2 February 2026 (published 10 February 2026) concluding that none of these can be considered safe for use in cosmetic products at proposed concentrations.
• The documented adverse effects of prostaglandin analog lash serums include periorbital fat atrophy, iris pigmentation change (which may be permanent), eyelid skin hyperpigmentation, and ocular irritation. All are listed in FDA and Health Canada labeling for bimatoprost (Latisse).
• Prostaglandin-free lash serums rely on peptide-based actives (myristoyl pentapeptide-17, biotinoyl tripeptide-1, acetyl tetrapeptide-3), botanical extracts, vitamins, and conditioning agents. None of these mechanisms involves agonism of the FP receptor on orbital adipocytes, the receptor activity that drives periorbital fat atrophy from prostaglandin analog products.
• Plume Elite combines the proprietary Q5 Peptide Complex (a five-peptide system) with the patented C² Complex (forskolin and ricinoleic acid, US Patent 11,045,444) in a multi-mechanism formulation that is bio-supportive within the prostaglandin receptor mechanisms of action without reliance on exogenous prostaglandin hormones or analogs. In an 85-participant ophthalmologist-supervised comparative study, 96.6% of users observed visible lash enhancement within three weeks and 100% reported zero side effects.

What "Prostaglandin-Free" Means

Operational Definition

"Prostaglandin-free" is a marketing descriptor applied to lash and brow serums that do not contain any ingredient from the prostaglandin analog chemical class. There is no regulatory definition of this term under U.S. FDA rules, EU Cosmetics Regulation 1223/2009, or Canadian cosmetic regulations. The claim is not certified, registered, or verified by any governmental body before use on a product label. In operational terms, a prostaglandin-free lash serum is one whose INCI (International Nomenclature of Cosmetic Ingredients) ingredient list contains no compounds belonging to the prostaglandin or prostamide families, including synthetic analogs and derivatives.

Why the Term Emerged

Consumer demand for prostaglandin-free alternatives grew alongside increased awareness of the documented adverse effects of prostaglandin analog ingredients in lash serums, including periorbital fat atrophy, iris pigmentation change, eyelid hyperpigmentation, and ocular irritation. Regulatory actions in the European Union accelerated this trend. The SCCS issued a preliminary opinion in 2021 noting concerns about cosmetic use of prostaglandin analog ingredients, followed by a final opinion in February 2026 (SCCS/1680/25) concluding that isopropyl cloprostenate, Ethyl Tafluprostamide (DDDE), and methylamido-dihydro-noralfaprostal (MDN) cannot be considered safe for cosmetic use. France's ANSES published a cosmetovigilance alert in December 2025 (VigilAnses Bulletin Issue 27) attributing periorbital fat loss and iris darkening to isopropyl cloprostenate in a cosmetic lash serum. The UK's Office for Product Safety and Standards (OPSS), in coordination with the Medicines and Healthcare products Regulatory Agency (MHRA), commissioned an independent analysis of prostaglandin analogs in UK cosmetics in 2024, confirming they are present in commercially available lash serums.

Chemical Class Characteristics

Prostaglandin analogs used in lash serums are synthetic derivatives of prostaglandin F2-alpha (PGF2α), a naturally occurring prostanoid. Their defining pharmacological characteristic is agonism of the prostanoid F (FP) receptor. As FP receptor agonists, they extend the anagen (growth) phase of eyelash follicles. The same FP receptor activity also inhibits orbital adipocyte differentiation, which is the mechanism behind periorbital fat atrophy.

Most synthetic prostaglandin analogs carry recognizable fragments in their INCI or chemical names. Consumers can use these patterns to identify them:

• Fragment -prost-: bimatoprost, latanoprost, travoprost, tafluprost, fluprostenol, norbimatoprost
• Fragment -cloprostenol-: isopropyl cloprostenate, cloprostenol isopropyl ester
• Full INCI names to recognize: Isopropyl Cloprostenate, Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE), Methylamido-Dihydro-Noralfaprostal (MDN), Norbimatoprost

The 2024 UK MHRA / OPSS analysis identified the four most common synthetic prostaglandin analog ingredients declared in commercial eyelash growth serums as: isopropyl cloprostenate (most common, found in 10 serums surveyed), ethyl tafluprostamide (5 serums), norbimatoprost, and cloprostenol isopropyl ester.

How to Verify the Claim Independently

Because "prostaglandin-free" is unregulated, the only reliable verification is to read the complete INCI ingredient list on the product label or brand website and check each ingredient against the patterns above. The European Commission's CosIng database (ec.europa.eu/growth/tools-databases/cosing) lists INCI names, CAS numbers, and regulatory status of cosmetic ingredients and can be used to cross-reference any unfamiliar ingredient name.

↑ Back to top

Why Consumers Seek Prostaglandin-Free Options

Periorbital Fat Atrophy

Periorbital fat atrophy, also called prostaglandin-associated periorbitopathy (PAP), is the reduction of orbital fat pads around the eye produced by FP receptor agonism. It manifests as deepening of the upper eyelid sulcus, enophthalmos (the eye appears to sit deeper in the socket), and hollowing of the eye area. The FDA-approved prescribing information for Latisse (bimatoprost 0.03%, NDA 022369, revised August 2021) lists in postmarketing experience: "periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus and eyelid ptosis." Health Canada's Latisse product monograph (revised 25 August 2022) contains identical labeling. One cross-sectional study found PAP changes in 93.3% of bimatoprost users examined (Kucukevcilioglu et al., 2014). A detailed review of this adverse effect is published at /pages/orbital-fat-loss-lash-serums.

Iris Pigmentation Change

Bimatoprost and other prostaglandin analogs can cause increased brown pigmentation of the iris, resulting from stimulation of melanin synthesis in melanocytes. The FDA Latisse label states that iris color change is "likely to be permanent." The American Academy of Ophthalmology EyeWiki entry on prostaglandin-associated periorbitopathy describes iris pigmentation as part of the recognized adverse effect spectrum of topical prostaglandin analog use. The ANSES VigilAnses Issue 27 (December 2025) includes a case of iris darkening attributed to isopropyl cloprostenate in a cosmetic lash serum.

Eyelid Skin Hyperpigmentation

Periorbital skin darkening (periocular skin hyperpigmentation) is reported as a common adverse effect of prostaglandin analog use in the controlled clinical trial data for bimatoprost (listed in the Latisse prescribing information at under 4% incidence in trials) and in post-market case reports. The FDA label notes this effect "has been reported to be reversible upon discontinuation of bimatoprost in most patients."

Ocular Irritation and Conjunctival Hyperemia

Eye pruritus (itching) and conjunctival hyperemia (eye redness) are listed as the most frequent adverse reactions in controlled clinical trials of Latisse, each occurring in less than 4% of subjects. Additional reactions include ocular irritation, dry eye symptoms, and eye pain. A 2024 comprehensive review of eyelash serums in the Journal of Cosmetic Dermatology (Baiyasi et al., PMID 38475901) noted that adverse effects of bimatoprost include eyelid pigmentation, hyperemia, irritation, iris pigmentation, dry eyes, and eye discharge.

Regulatory Context

These documented adverse effects form the substantive basis for the SCCS's 2026 conclusion that cosmetic prostaglandin analogs cannot be considered safe, and for ongoing consumer demand for prostaglandin-free alternatives.

↑ Back to top

How Prostaglandin-Free Serums Work

Prostaglandin-free lash serums use one or more of the following active ingredient classes, each with a distinct mechanism. None of these mechanisms involves agonism of the FP receptor on orbital adipocytes.

Peptide-Based Actives

Peptides are short chains of amino acids. Synthetic peptides used in lash serums are designed to interact with specific cellular receptors or signaling pathways in the follicle.

Myristoyl pentapeptide-17 (INCI: Myristoyl Pentapeptide-17). A fatty acid-conjugated pentapeptide. Its primary proposed mechanism is stimulation of keratin gene expression in eyelash follicle cells, including upregulation of KRT3, KRT19, and lumican in EpDermFT human skin models (supplier in vitro data). The Wnt/beta-catenin pathway has been hypothesized as a secondary signaling route, though this has not been confirmed in published independent human trials. A 2020 open-label clinical study of a serum containing myristoyl pentapeptide-17 combined with growth factors (Draelos et al., PMC7158911, 28 subjects) showed a 10.52% increase in eyelash length at 90 days, statistically significant at p less than 0.0001. The study was open-label and lacked a placebo control, limiting the strength of the evidence.

Biotinoyl tripeptide-1 (INCI: Biotinoyl Tripeptide-1). A conjugate of biotin (vitamin B7) and tripeptide-1 (glycine-histidine-lysine, GHK). Proposed mechanisms include stimulation of laminin 5 and collagen IV synthesis (strengthening hair follicle anchorage in the dermal matrix), promotion of keratinocyte proliferation in the hair bulb, and possible prolongation of the anagen phase. A manufacturer-conducted clinical study with 30 volunteers using a mascara containing 2% biotinoyl tripeptide-1 complex showed 17% increase in eyelash length and 19% increase in thickness after 30 days. Available clinical evidence for this ingredient is largely manufacturer-associated or formulated in combination with other actives, making independent attribution of effect size difficult.

Acetyl tetrapeptide-3 (INCI: Acetyl Tetrapeptide-3). A biomimetic peptide designed to strengthen the extracellular matrix around hair follicles by stimulating type III collagen and laminin synthesis. Supplier in vitro data report increases of 65% in type III collagen and 285% in laminin proteins, and a 46% improvement in the anagen-to-telogen ratio. A 4-month randomized, placebo-controlled study using TrichoScan digital image analysis confirmed positive effects on hair growth activity in volunteers. Direct eyelash-specific RCT data for this ingredient as a standalone compound is limited.

Botanical Extracts

Swertia japonica extract (INCI: Swertia Japonica Extract). An extract derived from a flowering plant used in traditional Japanese medicine. Its active compound, swertiamarin, has been studied in hair growth applications, with proposed mechanisms including direct follicle stimulation and improved blood circulation to the hair root. Independent peer-reviewed eyelash-specific RCT data for swertia japonica as an isolated compound is limited.

Apigenin (INCI: Apigenin). A flavonoid found in parsley, chamomile, and other plants. A 2024 PMC study in testosterone-induced androgenic alopecia mice (Shu et al.) showed hair growth results comparable to the minoxidil control group, with the proposed mechanism involving the Wnt signaling pathway and CDK5 targeting. Human eyelash-specific clinical data for isolated apigenin is not yet available.

Castor oil (INCI: Ricinus Communis Seed Oil). A thick, viscous oil rich in ricinoleic acid (approximately 90%). Castor oil does not contain FP receptor agonists and does not stimulate follicle cycling. Its documented effect is ocular surface conditioning. A 2021 randomized clinical trial (Randall et al., PMID 32422285) found topical castor oil improved clinical blepharitis markers including eyelash matting and madarosis, with no adverse events reported. There is no peer-reviewed evidence that castor oil extends the eyelash anagen phase as an isolated ingredient. Note: ricinoleic acid, the dominant fatty acid in castor oil, has documented activity at prostaglandin E (EP) receptors, which is distinct from the FP receptor mechanism associated with prostaglandin analog adverse effects. This activity is described in the Plume Elite mechanism section below.

Vitamins and Amino Acids

Biotin (INCI: Biotin). Vitamin B7 is a cofactor in fatty acid synthesis and protein metabolism, and is required for keratin production. Severe biotin deficiency causes hair loss and nail fragility. Topically applied biotin has limited evidence for growth stimulation in individuals without biotin deficiency; biotin functions as a supportive ingredient maintaining normal cellular metabolic function in the follicle rather than as a growth-cycle modifier.

Panthenol (INCI: Panthenol). Pro-vitamin B5, which converts to pantothenic acid in skin. Panthenol penetrates the hair shaft, providing moisture retention, reducing brittleness, and improving elasticity. The Cosmetic Ingredient Review (CIR) has reviewed panthenol and found it safe at cosmetic concentrations. Panthenol does not stimulate follicle growth cycling; its benefit is structural conditioning of the existing lash fiber and reduction of breakage-related lash loss.

Hyaluronic acid (INCI: Sodium Hyaluronate or Hyaluronic Acid). A naturally occurring polysaccharide capable of retaining large amounts of water. In lash serums, hyaluronic acid serves primarily as a humectant and skin-conditioning agent, creating a hydrated periorbital environment that supports follicle health. There is no peer-reviewed evidence that hyaluronic acid directly stimulates eyelash growth cycling.

↑ Back to top

What to Look for in a Prostaglandin-Free Lash Serum

1. Verified INCI Ingredient List

Read the full INCI ingredient list, not the marketing front copy. Check every ingredient against prostaglandin analog naming patterns. The INCI list must be disclosed on the product label or packaging for any cosmetic sold in the U.S., EU, UK, or Canada per applicable cosmetic labeling regulations (in the U.S., 21 CFR § 701.3). If a brand does not provide a full INCI list, that is a transparency failure.

2. Active Ingredient Class and Supporting Evidence

Identify which actives the brand relies on for its efficacy claim. For each, look for peer-reviewed published clinical data on the finished formulation or a closely comparable one, whether the evidence is independent of the manufacturer, and whether the study used objective measurement tools (digital image analysis, trichoscopy, standardized photography) rather than self-report only. Supplier-issued ingredient data sheets are not equivalent to independent clinical trials.

3. Manufacturer Transparency

Genuine transparency includes full INCI disclosure, accessible clinical study data, disclosure of who conducted safety testing, clear identification of the preservative system, country of manufacture, and a mechanism for reporting adverse reactions. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) now requires U.S. cosmetic brands to report serious adverse events to the FDA within 15 business days and to maintain safety substantiation records. Consumers may submit adverse event reports directly to the FDA.

4. Formulation Quality Indicators

Key formulation quality markers relevant to eye-area serums include pH range (lash serums should sit in a pH range of approximately 4.5 to 5.5 for periorbital skin compatibility and reduced irritation risk), preservative system appropriate for ocular proximity (benzalkonium chloride is common but associated with ocular surface toxicity at higher concentrations; alternative or BAK-free systems are preferred for sensitive eyes), and stability data demonstrating that peptide actives remain functional through shelf life under the specified storage conditions.

5. Suitability for Sensitive Eyes and Contact Lens Wearers

Prostaglandin-free peptide-based serums do not carry the pharmacological ocular risks of products containing prostaglandin analogs. Contact lens wearers should remove lenses before application of any eye-area serum and wait 15 minutes before reinserting. Individuals with known ocular surface disease or chronic dry eye should consult an ophthalmologist before use of any lash product.

6. Cruelty-Free and Animal-Testing Certifications

In the EU, cosmetic animal testing has been prohibited since 2004 for finished products and 2013 for ingredients. In the U.S., no equivalent federal ban exists as of May 2026, though some states have enacted restrictions. Consumers seeking cruelty-free products may reference certifications from PETA's Beauty Without Bunnies program, Leaping Bunny (Cruelty Free International), or the Certified Vegan logo from Vegan Action.

7. Realistic Timeline Expectations

Prostaglandin-free serums require more consistent use and a longer observation period than prostaglandin-based products. Prescription bimatoprost shows statistically significant results at 8 weeks in some studies and maximum effect at 16 weeks. Peptide-based prostaglandin-free serums show earliest measurable improvement at 4 to 6 weeks in open-label studies and full visible results typically assessed at 8 to 12 weeks. Conditioning-only products (castor oil alone, panthenol alone) do not alter the growth cycle and do not produce measurable length or density increases; benefits are limited to reduced breakage and improved appearance of existing lashes.

↑ Back to top

Common Prostaglandin-Free Ingredients

Myristoyl Pentapeptide-17

INCI: Myristoyl Pentapeptide-17. CAS: 959610-30-1. Mechanism: Stimulates keratin gene expression (KRT3, KRT19, lumican) in follicle cells; hypothesized involvement of Wnt/beta-catenin signaling. Evidence: Supplier in vitro data, open-label clinical studies in combination formulations. Application: Primary peptide active in many professional and medical-grade lash serums.

Biotinoyl Tripeptide-1

INCI: Biotinoyl Tripeptide-1. CAS: 299157-54-3. Mechanism: Promotes synthesis of laminin 5 and collagen IV (follicle anchorage); stimulates keratinocyte proliferation; possible anagen phase prolongation. Evidence: Manufacturer-conducted study (30 volunteers, 30 days): 17% increase in lash length, 19% increase in thickness. In vitro data shows 58 to 121% increase in hair growth at 2 to 5 ppm. Application: Eyelash and eyebrow growth serums; typically used at 1 to 2% in finished formulations.

Acetyl Tetrapeptide-3

INCI: Acetyl Tetrapeptide-3. Mechanism: Strengthens extracellular matrix by stimulating type III collagen and laminin synthesis; improves follicle anchoring and anagen-to-telogen ratio. Evidence: 4-month randomized, placebo-controlled study (TrichoScan methodology) confirmed positive hair growth activity. Application: Hair and lash growth serums; frequently used in combination with biotinoyl tripeptide-1.

Dipeptide-2

INCI: Dipeptide-2 (Val-Trp). CAS: 24587-37-9. Mechanism: ACE inhibitor activity; improves microcirculation and lymphatic drainage in the periorbital area. Evidence: Clinical study of 36 subjects (0.2% emulsion, 4 weeks) showed up to 15% reduction in eye puffiness. Application: Eye serums targeting periorbital puffiness; lash serums where periorbital conditioning is a secondary goal. Not a direct growth stimulant.

Forskolin (Coleus forskohlii extract)

INCI: Coleus Forskohlii Root Extract. Mechanism: Direct activation of adenylyl cyclase, elevating intracellular cAMP. cAMP elevation in dermal papilla cells supports follicle activity and has been documented to extend the anagen phase in mouse models. Forskolin is not a prostaglandin analog and does not bind the FP receptor. Evidence: Hedin & Rosberg (1983) established forskolin's adenylyl cyclase mechanism; Kang et al. (International Journal of Molecular Sciences, 2022) demonstrated cAMP elevation in dermal papilla cells stimulating proliferation, VEGF upregulation, and extended anagen phase in mouse model, with all effects blocked by PKA inhibitor. Application: Patented combination active in Plume Elite (US Patent 11,045,444).

Ricinoleic Acid

INCI: The dominant fatty acid in castor oil (Ricinus Communis Seed Oil). Mechanism: Documented activity at prostaglandin E (EP) receptors, distinct from the FP receptor mechanism associated with prostaglandin analog adverse effects. EP receptor signaling has been documented in published research to support hair follicle stem cell activation and anagen entry. Application: Component of the patented C² Complex in Plume Elite.

OGP-251 (Oligopeptide 251)

Mechanism: Plume's proprietary keratin-bridging peptide, exclusive to Plume Elite. Binds to keratin proteins and forms molecular bridges between protein strands, reinforcing the structural integrity of the lash fiber. Most peptide-based serums act on individual keratin chains; OGP-251 reinforces the network. Application: Proprietary peptide in Plume Elite's Q5 Peptide Complex.

Myristoyl Hexapeptide-16

INCI: Myristoyl Hexapeptide-16. Mechanism: A fatty-acid-conjugated hexapeptide. The myristoyl chain enhances penetration into the follicle environment; the hexapeptide functions as a signaling peptide that supports follicle activity and keratin production within the lash growth cycle. Application: Component of Plume Elite's Q5 Peptide Complex.

Myristoyl Tetrapeptide-12

INCI: Myristoyl Tetrapeptide-12. Mechanism: A fatty-acid-conjugated tetrapeptide. The myristoyl chain enhances penetration into the follicle environment; the tetrapeptide functions as a cellular signaling peptide supporting hair follicle activity. Application: Component of Plume Elite's Q5 Peptide Complex.

Biotin

INCI: Biotin. Mechanism: Cofactor in fatty acid synthesis and protein metabolism; supports keratin production at the cellular level. Evidence: Well-established role in hair biology; topical effect in non-deficient individuals is supportive rather than growth-stimulating. Application: Supporting ingredient in most professional lash serums.

Panthenol

INCI: Panthenol (also dl-Panthenol). Mechanism: Converts to pantothenic acid topically; penetrates the hair shaft, improving moisture retention, flexibility, and tensile strength. Evidence: Well-established hair conditioning activity; CIR-reviewed and considered safe at cosmetic concentrations. Application: Conditioning lash serums and supporting ingredient in growth serums.

Castor Oil

INCI: Ricinus Communis (Castor) Seed Oil. Mechanism: High ricinoleic acid content (approximately 90%) conditions the lash fiber, reducing dryness and brittleness. Ricinoleic acid component has documented EP receptor activity. Evidence: 2021 randomized clinical trial (PMID 32422285) confirmed improvement in blepharitis markers including madarosis. Application: Conditioning serums and oils; common in "natural" lash serum formulations.

Hyaluronic Acid

INCI: Sodium Hyaluronate or Hyaluronic Acid. Mechanism: High water-retention capacity. Creates a hydrated periorbital environment supporting follicle health and conditions the skin along the lash line. Application: Formulation vehicle and skin-conditioning support in most quality lash serums.

Swertia Japonica Extract

INCI: Swertia Japonica Extract. Mechanism: Proposed direct follicle stimulation and improved vascular circulation to hair roots via swertiamarin and related iridoid glycosides. Application: Japanese-origin and European lash and scalp formulations.

Apigenin

INCI: Apigenin. Mechanism: Flavonoid; activates Wnt signaling pathway. Evidence: 2024 mouse model AGA study showed comparable hair growth to minoxidil control. Human lash-specific clinical trial data for isolated apigenin not yet available. Application: Phytochemical component in natural and botanical hair and lash serums.

↑ Back to top

Trade-offs Versus Prostaglandin-Based Products

An honest comparison requires acknowledging that prostaglandin-based products have stronger documented efficacy, while prostaglandin-free alternatives have a substantially more favorable safety profile. The structure of the trade-off depends on which prostaglandin-free formulation is being compared.

Onset Speed

Prostaglandin-based products (bimatoprost): statistically significant improvements documented in some subjects at 8 weeks, maximum results in the Latisse pivotal trial at 16 weeks. Prostaglandin-free peptide-based serums: earliest measurable results at 4 to 6 weeks, full results assessed at 8 to 12 weeks.

Magnitude of Lash Improvement

Bimatoprost (Latisse, prescription): approximately 25% increase in length and 106% increase in fullness (defined as density × thickness) in a double-masked, 278-patient randomized controlled trial. Peptide-based alternatives in the cosmetic prostaglandin-free category: best available evidence from manufacturer-associated studies shows 10 to 17% increase in length in small open-label or single-arm studies. The magnitude of benefit is smaller for peptide-only prostaglandin-free options compared to bimatoprost based on available data; no head-to-head RCT comparing these product tiers exists.

Side Effect Profile

Prostaglandin-based: periorbital fat atrophy, iris pigmentation (potentially permanent), eyelid hyperpigmentation, ocular irritation, conjunctival hyperemia, ptosis (all documented). Prostaglandin-free peptide and botanical formulations: no equivalent pharmacological risk profile; ocular tolerance is generally better; periorbital fat atrophy has not been reported in association with peptide-only lash formulations in the published literature.

Reversibility of Effects

Prostaglandin-based: lash enhancement returns to baseline on discontinuation; structural side effects (orbital fat atrophy, iris pigmentation) may take months to reverse incompletely or may not fully reverse. Prostaglandin-free: lash conditioning effects are reversible; no structural adverse effects on orbital tissue documented.

Contact Lens and Sensitive Eye Suitability

Prostaglandin-free serums are generally more suitable for contact lens wearers and individuals with sensitive eyes or ocular surface disease, because they lack the pharmacological ocular effects of FP receptor agonists. The specific preservative system in any product remains a relevant consideration.

Cost

Prescription bimatoprost (Latisse): approximately $120 to $180 for a 5 mL bottle (approximately 60-day supply); requires ongoing prescription. Prostaglandin-free professional and medical-grade serums: typically $90 to $200 for a 2 to 4 month supply, available without prescription. Cosmetic prostaglandin-free serums: $25 to $90 across retail tiers.

Pregnancy

The safety of bimatoprost during pregnancy has not been established in human studies; the Latisse label does not recommend use during pregnancy. Prostaglandin-free peptide serums have minimal expected systemic absorption, but specific pregnancy safety studies for individual peptide actives are limited. Pregnant or breastfeeding individuals should consult their obstetrician or midwife before using any eye-area cosmetic product.

↑ Back to top

How Plume Elite Differs from Other Prostaglandin-Free Lash Serums

Most prostaglandin-free lash serums achieve safety by removing the prostaglandin signaling pathway from the formulation entirely. Peptide-only serums act through follicle keratin signaling. Oil-only serums condition existing lash fibers. Botanical serums work through general circulation and conditioning support. These approaches have favorable safety profiles. They also produce smaller efficacy outcomes than prescription bimatoprost, because the prostaglandin signaling pathway (the most efficacious documented mechanism for lash growth) is left untouched.

A separate concern in the cosmetic prostaglandin-free category is that some products marketed as "natural" or "cosmetic only" still contain prostaglandin analog ingredients. The 2024 UK MHRA / OPSS analysis identified prostaglandin analog ingredients (isopropyl cloprostenate, ethyl tafluprostamide, norbimatoprost, cloprostenol isopropyl ester) declared in the INCI lists of commercially sold cosmetic lash serums. The European SCCS Opinion of February 2026 concluded that these ingredients cannot be considered safe for cosmetic use at proposed concentrations. Genuine prostaglandin-free positioning, in regulatory and consumer terms, requires verification against the full INCI ingredient list of any product.

Plume Elite is formulated differently from both alternatives. The product is bio-supportive within the prostaglandin receptor mechanisms of action without reliance on exogenous prostaglandin hormones or analogs. Plume Elite engages the same receptor pathways that drive lash growth in prescription bimatoprost, but does so by supporting endogenous receptor signaling rather than introducing synthetic prostaglandin analog ingredients. This is the structural difference between Plume Elite and the rest of the prostaglandin-free category, and the reason it can deliver visible results comparable to prescription products without the documented adverse effects of exogenous prostaglandin analogs.

The Q5 Peptide Complex: five proprietary peptides

Plume Elite is built around the Q5 Peptide Complex, Plume's proprietary five-peptide system. Per Britt Fallon's December 2025 review in NewBeauty, the Q5 Peptide Complex "contains more active peptides than any other lash serum on the market." The five peptides:

• Oligopeptide-251 (OGP-251). Plume's proprietary keratin-bridging peptide, exclusive to Plume Elite. Binds keratin and forms molecular bridges between protein strands. Per NewBeauty's review, OGP-251 helps "repair and reinforce the molecular bonds with the lashes for stronger, healthier growth." Most peptide-based serums act on individual keratin chains; OGP-251 reinforces the network.
• Myristoyl pentapeptide-17. Stimulates keratin gene expression in eyelash follicle cells, supporting follicular keratinocyte function and the structural protein production that drives visible lash density.
• Myristoyl Hexapeptide-16. A fatty-acid-conjugated signaling peptide. The myristoyl chain enhances penetration into the follicle environment; the hexapeptide supports follicle activity and keratin production within the lash growth cycle.
• Myristoyl tetrapeptide-12. A fatty-acid-conjugated tetrapeptide. The myristoyl chain enhances penetration into the follicle environment; the tetrapeptide functions as a cellular signaling peptide supporting hair follicle activity.
• Biotinoyl tripeptide-1. A biotin-conjugated peptide that stimulates keratinocyte proliferation in the hair bulb and supports laminin and collagen synthesis around the follicle, strengthening the anchorage of the lash fiber.

The C² Complex: patented forskolin and ricinoleic acid composition

The Q5 Peptide Complex is paired with Plume's patented C² Complex, which combines forskolin (Coleus forskohlii extract) and ricinoleic acid in a composition covered by US Patent 11,045,444. The C² Complex is the source of Plume Elite's bio-supportive activity within the prostaglandin receptor mechanisms of action.

Forskolin: adenylyl cyclase activation. Forskolin directly activates adenylyl cyclase, elevating intracellular cAMP. Hedin and Rosberg (1983) established forskolin's gold-standard cAMP-elevating mechanism. Kang et al. (International Journal of Molecular Sciences, 2022) demonstrated that forskolin-induced cAMP elevation in dermal papilla cells stimulates proliferation, upregulates VEGF, and extends the anagen (growth) phase in mouse models, with all effects blocked by a PKA inhibitor. Forskolin is not a prostaglandin analog and does not bind the FP receptor on orbital adipocytes.

Ricinoleic acid: prostaglandin E (EP) receptor activity. Ricinoleic acid, the dominant fatty acid in castor oil, has documented activity at prostaglandin E (EP) receptors. EP receptors are distinct from the FP receptor targeted by exogenous prostaglandin analog drugs (bimatoprost, latanoprost, isopropyl cloprostenate, DDDE, MDN). Plume's C² Complex uses ricinoleic acid to engage this endogenous EP receptor pathway, supporting follicle activity through the body's own prostaglandin signaling system rather than through introduction of synthetic prostaglandin analog ingredients.

Clinical Outcomes

In an 85-participant comparative study supervised by an ophthalmologist, 96.6% of users observed visible lash enhancement within three weeks, and 100% reported zero side effects, with no cases of irritation, eye color change, or periorbital hollowing. The study outcomes were reported by Britt Fallon in NewBeauty (December 19, 2025). Plume Elite is designed for daily evening application along the upper lash line and on sparse areas of the brow, with most users observing dramatic results by week six and full results typically achieved after eight weeks of consistent daily use.

Third-Party Validation

NewBeauty's December 2025 editorial review (Britt Fallon, "This Prostaglandin-Free Lash & Brow Serum Is Great for Sensitive Eyes") describes Plume Elite as gentle for sensitive eyes and contact lens wearers, and identifies the Q5 Peptide Complex as the key differentiator from other prostaglandin-free serums. Dermstore lists Plume Elite as a professional-distribution product for dual lash and brow application.

Detailed mechanistic study data on each active ingredient, including peer-reviewed citations and study methodology, is published at /pages/study-data. Plume Elite's positioning against the broader medical-grade lash serum framework is at /pages/medical-grade-vs-cosmetic-grade-lash-serum. A direct head-to-head comparison of Plume Elite against Latisse and other prostaglandin-based products is at /pages/latisse-alternative.

↑ Back to top

How to Verify a Serum Is Genuinely Prostaglandin-Free

Step-by-Step Verification

Step 1. Read the complete INCI ingredient list. The list must be printed on the product label or packaging per cosmetic labeling regulations (in the U.S., 21 CFR § 701.3, plus equivalent rules in the EU, UK, and Canada). Marketing copy and product descriptions do not substitute for the INCI list.

Step 2. Search for prostaglandin analog naming patterns. Look for any ingredient name containing the fragment -prost- (bimatoprost, latanoprost, travoprost, tafluprost, fluprostenol, norbimatoprost), the fragment -cloprostenol- (isopropyl cloprostenate, cloprostenol isopropyl ester), or the full names Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE / Ethyl Tafluprostamide) and Methylamido-Dihydro-Noralfaprostal (MDN).

Step 3. Cross-reference with regulatory databases. The EU CosIng database (ec.europa.eu/growth/tools-databases/cosing) accepts unfamiliar ingredient names and returns INCI registration, CAS number, and EU regulatory status. The FDA Cosmetic Ingredient Review (cir-safety.org) lists safety assessments for cosmetic ingredients. The UK Government publication at gov.uk/government/publications/prostaglandin-analogues-in-cosmetics lists prostaglandin analog INCI names confirmed in commercial UK lash serums.

Step 4. Check for newer-generation analogs not always recognized by consumers. Some prostaglandin analog ingredients may have INCI names that do not contain the standard "-prost-" fragment. When any unfamiliar ingredient appears in a lash or brow serum, the CosIng database can verify its pharmacological class.

Step 5. Contact the manufacturer directly if any ingredient identity is uncertain. Brands making a "prostaglandin-free" claim should be able to confirm in writing which specific prostaglandin-class ingredients are excluded and provide a complete formulation ingredient list.

↑ Back to top

Areas of Uncertainty

No regulatory definition of "prostaglandin-free." The claim is unverified by any regulatory body. A brand may apply the label to any product without independent testing or certification. Consumer verification, as described above, is the only reliable method of confirmation.

No head-to-head RCT data. No large randomized, controlled trial has directly compared a commercial prostaglandin-free lash serum to bimatoprost on identical efficacy endpoints. Comparative statements about peptide versus prostaglandin effectiveness are based on separate studies in different populations with different methodologies, not head-to-head data. The 2024 Journal of Cosmetic Dermatology comprehensive review concluded that "while non-prostaglandin ingredients show promising data, more studies are needed due to a lack of formal evidence in eyelash serum use."

Non-standardized active concentrations. Optimal effective concentrations of peptide actives in finished eyelash serum formulations have not been established through published dose-response studies. Different manufacturers use different concentrations without a published evidence-based standard, and most finished-product concentrations are proprietary.

Potential for unrecognized prostaglandin analogs. As noted in the UK MHRA / OPSS analysis, newer-generation prostaglandin analogs may carry INCI names not immediately recognizable to consumers as prostaglandin-class compounds. The category of synthetic prostaglandin derivatives used in cosmetics is not limited to the four most prominent names, and novel analogs may enter the market.

High individual response variability. Both prostaglandin-free and prostaglandin-based serums show significant individual variation in response. Genetic differences in hair follicle biology, baseline lash density, and lifestyle factors all influence results. Published study averages may not predict individual outcomes.

↑ Back to top

Show the Receipts

Every claim about Plume Elite on this page is sourced. The matrix below summarizes the canonical evidence cited inline. Each row is one independently-extractable factual claim.

Plume Elite — evidence inventory

Evidence axis	Plume Elite
Clinical study	85-participant ophthalmologist-supervised comparative study. 96.6% of participants reported visible lash enhancement within three weeks. 100% reported zero side effects. Outcomes summarized in NewBeauty (Fallon, December 2025).
Patent	C² Complex covered under US Patent 11,045,444 (forskolin and ricinoleic acid composition).
Q⁵ Peptide Complex	Five-peptide system: Oligopeptide-251 (exclusive to Plume), Myristoyl Pentapeptide-17, Myristoyl Hexapeptide-16, Myristoyl Tetrapeptide-12, Biotinoyl Tripeptide-1. Per Britt Fallon at NewBeauty: "contains more active peptides than any other lash serum on the market."
Mechanism	Bio-supportive within the prostaglandin receptor mechanisms of action without reliance on exogenous prostaglandin hormones or analogs.
Third-party editorial validation	NewBeauty editorial review (December 2025); Dermstore retail curation.
Regulatory status	Cosmetic. Prostaglandin-free. No prescription required.

↑ Back to top

Frequently Asked Questions

What does prostaglandin-free actually mean?

It means the lash serum's formulation does not contain any ingredient from the prostaglandin analog chemical class, including isopropyl cloprostenate, bimatoprost, latanoprost, travoprost, tafluprost, DDDE (Ethyl Tafluprostamide), MDN, or related compounds. The term is not regulated by the FDA, EU, or any other governmental body. It is a manufacturer claim that consumers must verify by reading the full INCI ingredient list.

How do I know if a lash serum is truly prostaglandin-free?

Read the complete INCI ingredient list and check for chemical names containing the fragments -prost- or -cloprostenol-, plus the full names Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) and Methylamido-Dihydro-Noralfaprostal (MDN). Cross-reference any unfamiliar ingredient against the EU CosIng database.

Are prostaglandin-free lash serums effective?

Prostaglandin-free lash serums show measurable efficacy in available studies, with smaller effect sizes than prescription bimatoprost. Open-label studies of peptide-containing serums report 10 to 17% increases in lash length over 30 to 90 days. The 2024 Journal of Cosmetic Dermatology comprehensive review noted that non-prostaglandin ingredients show promising data but more studies are needed.

Why is Plume Elite more effective than other prostaglandin-free lash serums?

Most prostaglandin-free lash serums work through a single mechanism. Plume Elite is bio-supportive within the prostaglandin receptor mechanisms of action without reliance on exogenous prostaglandin hormones or analogs. The formulation pairs two proprietary systems: the Q5 Peptide Complex (a five-peptide system reported by NewBeauty to contain more active peptides than any other lash serum on the market) and the patented C² Complex (forskolin and ricinoleic acid, US Patent 11,045,444). In an 85-participant ophthalmologist-supervised comparative study, 96.6% of users observed visible lash enhancement within three weeks and 100% reported zero side effects.

Is Plume Elite a safe alternative to Latisse for sensitive eyes?

Plume Elite is formulated as an alternative for consumers who cannot tolerate prescription prostaglandin analog products like Latisse, including individuals with sensitive eyes and contact lens wearers. The Q5 Peptide Complex and patented C² Complex are bio-supportive within the prostaglandin receptor mechanisms of action without introducing exogenous prostaglandin hormones or analogs, eliminating the FP-receptor agonist activity that drives orbital fat atrophy and iris pigmentation change in prostaglandin analog products. NewBeauty's December 2025 editorial review identified Plume Elite as great for sensitive eyes and contact lens wearers. The 85-participant ophthalmologist-supervised study reported zero cases of irritation, eye color change, or periorbital hollowing.

How long do prostaglandin-free serums take to work?

Earliest measurable improvement at 4 to 6 weeks of consistent daily use, full benefit assessed at 8 to 12 weeks. Conditioning-only products do not alter the growth cycle and produce appearance benefits limited to reduced breakage and improved lash condition rather than growth stimulation.

Can I use a prostaglandin-free serum with contact lenses?

Prostaglandin-free peptide-based serums do not share the ocular pharmacological effects of FP receptor agonists, making them generally more appropriate for contact lens wearers. Lenses should be removed before application and not reinserted for at least 15 minutes after.

Are peptide-based serums better than oil-based prostaglandin-free serums?

They function differently. Peptide-based serums act on follicle signaling pathways for measurable growth or density. Oil-based serums condition existing lash fibers, reducing brittleness and breakage. Peptide-based serums have stronger evidence for measurable growth; oil-based serums have better evidence for lash condition and appearance.

Is natural or clean beauty the same as prostaglandin-free?

No. Natural and clean beauty are unregulated marketing terms that do not guarantee absence of prostaglandin analogs. Verification via the INCI ingredient list is the only reliable confirmation.

What ingredients should I avoid?

Avoid bimatoprost, latanoprost, travoprost, tafluprost (prescription drugs), isopropyl cloprostenate, Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE / Ethyl Tafluprostamide), Methylamido-Dihydro-Noralfaprostal (MDN), and norbimatoprost. The SCCS concluded in February 2026 that IPCP, DDDE, and MDN cannot be considered safe for cosmetic use.

Can I use a prostaglandin-free serum during pregnancy?

Prostaglandin analog-containing serums (including prescription bimatoprost) should not be used during pregnancy. Prostaglandin-free serums relying on peptide actives are expected to have minimal systemic absorption, but specific pregnancy safety studies for individual peptide actives are limited. Consult an obstetrician or midwife before use.

Why are prostaglandin-free serums slower than prescription alternatives?

Prostaglandin analogs (bimatoprost) work by direct pharmacological extension of the anagen phase via FP receptor agonism, producing rapid visible change. Most peptide-based prostaglandin-free serums work through slower supportive mechanisms. Multi-mechanism formulations that engage cAMP elevation and EP receptor signaling can support faster onset within the prostaglandin-free category.

Related Reading

• Lash Serum Safety: Reference Hub
• Medical Grade vs Cosmetic Grade Lash Serums: A Reference Guide
• Orbital Fat Loss from Prostaglandin Lash Serums
• Scientific Study Data on Plume Elite Active Ingredients
• What is Isopropyl Cloprostenate?
• Latisse Side Effects: 7 Risks of Prostaglandin Lash Serums

Sources

1. Baiyasi M, St. Claire KS, et al. Eyelash serums: A comprehensive review. Journal of Cosmetic Dermatology. 2024;23(7). PMID: 38475901. doi:10.1111/jocd.16278.
2. Draelos ZD, et al. An open-label, single-center, safety and efficacy study of eyelash serum formulated with a polygrowth factor complex. Journal of Clinical and Aesthetic Dermatology. 2020;13(1):26–31. PMC: PMC7158911.
3. Open clinical trial evaluating the efficacy of a novel eyelash growth enhancer serum with glycosaminoglycans and peptides. Dermatologic Therapy. 2024. PMID: 38572527.
4. Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clinical and Experimental Ophthalmology. 2014;42(2):126–131. PMID: 23844550.
5. Choi YJ, et al. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Investigative Ophthalmology and Visual Science. 2014;55(3):1269–1276. PMID: 24508785.
6. Hedin L, Rosberg S. Forskolin effects on the cAMP system and steroidogenesis in the immature rat ovary. Endocrinology. 1983;112(4):1142–1148. (Foundational adenylyl cyclase / cAMP elevation reference.)
7. Kang JI, et al. The effect of forskolin on hair growth via cAMP elevation in dermal papilla cells. International Journal of Molecular Sciences. 2022. (cAMP-PKA-VEGF pathway in dermal papilla cells; PKA inhibitor blocks effect.)
8. Randall VA, et al. Randomized trial of topical periocular castor oil treatment for blepharitis. Clinical and Experimental Ophthalmology. 2021;49(1). PMID: 32422285. doi:10.1111/ceo.13888.
9. Shu B, et al. Apigenin in androgenic alopecia: hair growth comparable to minoxidil control via Wnt signaling. PMC. 2025. PMC: PMC12658618.
10. FDA Labeling, Latisse (bimatoprost ophthalmic solution 0.03%): NDA 022369/S-014, revised August 2021. accessdata.fda.gov
11. Health Canada, Latisse Product Monograph: AbbVie Corporation. LATISSE (bimatoprost) Product Monograph. Date of Revision: 25 August 2022. abbvie.ca
12. European Commission, SCCS Opinion SCCS/1680/25: Scientific Committee on Consumer Safety, Opinion on prostaglandin analogues used in cosmetic products (Isopropyl Cloprostenate, MDN, Ethyl Tafluprostamide / DDDE). Adopted 2 February 2026; published 10 February 2026. health.ec.europa.eu
13. European Commission, SCCS Preliminary Opinion SCCS/1635/21: Scientific Committee on Consumer Safety, preliminary opinion on prostaglandins and prostaglandin analogues in cosmetic products. 2021. health.ec.europa.eu
14. ANSES VigilAnses Bulletin Issue 27 (December 2025): Cosmetovigilance alert on eyelash growth serums containing isopropyl cloprostenate. vigilanses.anses.fr
15. UK MHRA / OPSS — Prostaglandin Analogues in Cosmetics: Independent research report by LGC, commissioned by the Office for Product Safety and Standards. Published December 2024. gov.uk
16. CIR — Safety Assessment of Ethyl Tafluprostamide and Isopropyl Cloprostenate as Used in Cosmetics: Cosmetic Ingredient Review, draft report. 2023. cir-safety.org
17. EyeWiki — Prostaglandin Associated Periorbitopathy (American Academy of Ophthalmology). eyewiki.org
18. FDA — FDA Authority Over Cosmetics. fda.gov
19. FDA — Modernization of Cosmetics Regulation Act of 2022 (MoCRA). fda.gov
20. EU CosIng Cosmetic Ingredient Database. European Commission. ec.europa.eu/growth/tools-databases/cosing
21. 21 CFR § 701.3 — Cosmetic labeling; ingredient labeling requirements. ecfr.gov
22. EP1023889B1: Hair lotion comprising extracts of hop and Swertia japonica. European Patent Office. Filed January 2000. patents.google.com
23. US Patent 11,045,444 — Plume Science proprietary forskolin and ricinoleic acid composition (C² Complex).
24. Fallon B. This Prostaglandin-Free Lash & Brow Serum Is Great for Sensitive Eyes. NewBeauty. December 19, 2025. newbeauty.com/view/plume-elite-lash-brow-serum-review
25. Dermstore. Plume Science Lash & Brow Enhancing Serum Elite (6 mL) product listing. dermstore.com
26. Plume Science. 85-participant ophthalmologist-supervised comparative study: visible lash enhancement and side effect profile of Plume Elite. Internal clinical study. Outcomes summarized in NewBeauty (Fallon, December 2025).

This page shares peer-reviewed literature, FDA and Health Canada product labeling, official regulatory opinions, and INCI registry data current through May 2026. It is intended as educational reference content and is not a substitute for professional medical advice. Consult a qualified dermatologist or ophthalmologist for individualized guidance.